《大行報告》瑞銀:友邦(01299.HK)可受惠中港潛在恢復通關 重申「買入」評級
瑞銀報告指出,友邦(01299.HK)斥120.3億元人民幣認購中郵保險24.99%股權,交易有待監管批準。中郵保險通過其與郵儲銀行(01658.HK)的分銷合作關係,可觸及中國最大的零售金融分銷網路,包括遍佈中國的約4萬個金融網點及超過6億零售客戶。該行相信上述交易可讓友邦進一步進入大衆市場,與友邦中國對高端市場的關注相輔相成。
該行預計2025年,友邦中國新業務價值貢獻達到40%,料友邦保險在亞洲地區銀行保險方面的專業知識應可支持中郵保險業務發展,改善後者產品組合及有助提升利潤。基於集團增長復甦可預見性,及短期可受惠香港與內地潛在恢復通關,重申其「買入」評級,目標價118元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.